Nevro

Nevro's mission is to free patients from the burden of chronic pain through its innovative neuromodulation technology. Its key achievement was the 2015 FDA approval of the Senza SCS System for 10 kHz Therapy, establishing a new standard in paresthesia-free spinal cord stimulation. The company's strategy centers on its comprehensive HFX solution, which integrates proprietary high-frequency stimulation, multi-waveform capabilities, and extensive clinical support to drive adoption in the large and growing chronic pain market. Nevro has expanded globally, treating tens of thousands of patients and securing specific FDA indications for conditions like painful diabetic neuropathy.

The HFX platform is a comprehensive spinal cord stimulation (SCS) system built around proprietary 10 kHz Therapy, which provides pain relief without paresthesia, and is capable of delivering all available SCS frequencies and waveform types from a single implantable pulse generator.

Nevro competes in the spinal cord stimulation market against well-capitalized giants Medtronic, Boston Scientific, and Abbott. While competitors have developed their own advanced waveforms, Nevro differentiates itself with its first-mover advantage in paresthesia-free 10 kHz Therapy, a strong foundation of clinical evidence, and specific FDA labels for PDN and NSBP.